Belgium does not get the attention it deserves in life sciences conversations. While everyone talks about Boston and Basel, Belgium quietly built one of the densest biotech ecosystems in the world. UCB in Brussels, Janssen (Johnson & Johnson's pharmaceutical arm) in Beerse, Galapagos in Mechelen, argenx with major operations in Ghent, and a growing cluster of cell and gene therapy companies around the university hospitals in Leuven and Ghent. Per capita, Belgium has more biotech companies then almost any country outside of the United States. And the validation landscape here has its own distinct character.
FAMHP and the Belgian inspection culture
The Federal Agency for Medicines and Health Products (FAMHP, or FAGG in Dutch) is Belgium's competent authority. Belgian GMP inspections are thorough and increasingly focused on computerised system validation and data integrity — reflecting the broader EU trend. What makes Belgium different is the practical reality of operating in a small country with a dense pharmaceutical cluster: inspectors see a lot of different operations in a short period, which makes them experienced and hard to impress with surface-level compliance. They have seen every shortcut and every creative interpretation of the regulations. Your validation evidence needs to be genuine, not just technically present.
The Ghent-Leuven biotech corridor
The corridor between Ghent and Leuven is where Belgian biotech is concentrated. VIB (the Flanders Institute for Biotechnology) has been a catalyst for decades, spinning out companies and attracting talent. The cell and gene therapy cluster is particularly strong — driven by university hospital research programmes that translate directly into clinical development. For validation teams, this means working with companies that are often at the cutting edge of biological manufacturing, where the validated systems include not just standard LIMS and MES but also specialised cell processing platforms, gene vector manufacturing systems, and advanced therapy medicinal product (ATMP) tracking systems. These are GAMP 5 Category 5 systems with complex, custom-developed functionality that demands thorough, risk-based validation. GxP Copilot handles the classification and risk assessment for these novel systems with the same framework it uses for standard platforms.
The bilingual challenge
Belgium is officially trilingual — Dutch in Flanders, French in Wallonia, German in the east — and this creates a practical challenge for validation documentation. Companies operating across both regions may need SOPs and work instructions in both Dutch and French, while validation documentation itself is typically in English. The complexity is not just translation; it is maintaining consistency across language versions when procedures change. Your change control process needs to account for multilingual document updates, and your training programme needs to verify competency in the language the operator actually works in. This is one of those details that sounds minor until an inspector asks to see the French version of an SOP and your team realises it has not been updated to match the latest English revision.
Janssen and the Beerse effect
Janssen's global pharmaceutical R&D campus in Beerse is one of the largest pharmaceutical research sites in the world. Like Novo Nordisk in Denmark and Novartis in Switzerland, Janssen's presence shapes the expectations and practices of the entire Belgian pharmaceutical ecosystem. Their quality standards, validation practices, and supplier qualification requirements cascade through the supply chain. If you are a software vendor or service provider working in Belgian pharma you will eventually need to meet Janssen-level expectations, even if your direct client is a smaller company. The bar is high, but the market rewards companies that can meet it consistently.
What we see working in Belgian life sciences
- EU harmonisation is well understood. Belgian pharma teams navigate EU GMP confidently and generally stay current with Annex revisions and EMA guidance updates.
- Academic-industry collaboration is strong. University hospital partnerships mean that Belgian biotech companies often have deep scientific expertise in-house, which makes validation conversations more technically sophisticated.
- Pragmatic compliance culture. Belgian teams tend to be practical about compliance — thorough but not bureaucratic. Risk-based approaches like CSA are well-received.
- Excellent logistics position. Belgium's central European location makes it a natural hub for pharma distribution and clinical trial logistics, which adds cold-chain and GDP validation requirements to many companies' scope.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.